The week in health tech, explained in plain English.Get the free newsletter →
October 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

CMS Shaped AI Health Policy in a Private Slack

CMS officials helped shape federal AI healthcare policy inside a government-run Slack workspace of about 1,700 participants, most of them technology executives and investors, according to a KFF Health News investigation reported by HISTalk.

The concern is access and process. Federal rulemaking normally runs through public comment and documented channels that any stakeholder can see and join. A private Slack dominated by industry insiders gives a select group an informal line to policymakers, while patient advocates, clinicians, and the general public are left outside the room. That matters for AI specifically, where the rules will decide how algorithms are paid for, validated, and deployed across Medicare and Medicaid.

For health-tech leaders, the story is a signal that AI oversight is being written now, and that who participates shapes the outcome. Expect scrutiny of CMS over conflicts of interest and transparency, and potential pressure to move these conversations into the open. Watch for follow-up from oversight bodies and calls for a formal, auditable public process.

Sources

More in Government

Government

NIH Plans National Push on Personalized Cancer Vaccines

The NIH plans a December public-private partnership to accelerate development of personalized cancer vaccines, per a New York Times report.

Why it matters: A federally coordinated effort could accelerate a promising but fragmented field of custom cancer immunotherapies toward wider clinical use.

Government

White House Plans $100M STEM PhD Push as NIH Sheds Scientists

The Trump administration plans to put over $100 million into STEM PhD fellowships, announced at an Oct. 8 White House summit, even as the NIH loses scientists.

Why it matters: The PhD pipeline fuels biomedical research across hospitals and biotech, but new fellowship funding may not offset talent losses at the NIH.

Government

Stem Cell Advocates Eye FDA Opening Under RFK Jr.

Stem cell advocates hope the FDA will grant their unproven therapies legitimacy under RFK Jr., mirroring how peptides gained acceptance through the MAHA movement.

Why it matters: If regulatory politics rather than clinical evidence starts shaping FDA acceptance, it could reshape patient access and safety standards across emerging therapies.